110 related articles for article (PubMed ID: 19151562)
41. Dacetuzumab, a humanized mAb against CD40 for the treatment of hematological malignancies.
Khubchandani S; Czuczman MS; Hernandez-Ilizaliturri FJ
Curr Opin Investig Drugs; 2009 Jun; 10(6):579-87. PubMed ID: 19513947
[TBL] [Abstract][Full Text] [Related]
42. Longitudinal analysis and prognostic effect of cancer-testis antigen expression in multiple myeloma.
Atanackovic D; Luetkens T; Hildebrandt Y; Arfsten J; Bartels K; Horn C; Stahl T; Cao Y; Zander AR; Bokemeyer C; Kröger N
Clin Cancer Res; 2009 Feb; 15(4):1343-52. PubMed ID: 19190130
[TBL] [Abstract][Full Text] [Related]
43. [Detection of minimal residual disease in leukemia using flow cytometry].
Muroi K
Rinsho Ketsueki; 2008 Jun; 49(6):397-407. PubMed ID: 18646607
[No Abstract] [Full Text] [Related]
44. Partially matched related hematopoietic stem cell transplantation without ex vivo T cell depletion compared with matched unrelated transplantation in adult patients with hematologic malignancies.
Wang Y; Chen F; Han Y; Fu ZZ; Tang XW; Miao M; Qiu HY; Jin ZM; Sun AN; Wu DP
Biol Blood Marrow Transplant; 2009 Oct; 15(10):1258-64. PubMed ID: 19747633
[TBL] [Abstract][Full Text] [Related]
45. [Blastic plasmacytoid dendritic cell neoplasm - a rare differential diagnosis of neoplastic skin infiltrations associated with systemic symptoms].
Löffler H; Kosely F; Ho AD; Krämer A
Dtsch Med Wochenschr; 2009 Sep; 134(39):1927-30. PubMed ID: 19760552
[TBL] [Abstract][Full Text] [Related]
46. Peripheral blood progenitor cell collection without close monitoring of peripheral blood CD34+ cells: A feasible strategy for multiple myeloma or pre-treated Non-Hodgkin's Lymphoma patients mobilized with low-dose cyclophosphamide plus G-CSF.
Callera F; Cavenaghi L; de Melo CM
Transfus Apher Sci; 2009 Apr; 40(2):91-5. PubMed ID: 19233728
[TBL] [Abstract][Full Text] [Related]
47. Flow cytometric immunophenotyping and minimal residual disease analysis in multiple myeloma.
Gupta R; Bhaskar A; Kumar L; Sharma A; Jain P
Am J Clin Pathol; 2009 Nov; 132(5):728-32. PubMed ID: 19846814
[TBL] [Abstract][Full Text] [Related]
48. Partially matched related donor transplantation can achieve outcomes comparable with unrelated donor transplantation for patients with hematologic malignancies.
Xiao-Jun H; Lan-Ping X; Kai-Yan L; Dai-Hong L; Yu W; Huan C; Yu-Hong C; Wei H; Jing-Zhi W; Yao C; Xiao-Hui Z; Hong-Xia S; Feng-Rong W; Fei-Fei T
Clin Cancer Res; 2009 Jul; 15(14):4777-83. PubMed ID: 19584148
[TBL] [Abstract][Full Text] [Related]
49. [Multiple myeloma relapsed or progressed as plasmacytoma after allogeneic reduced-intensity stem cell transplantation: report of three cases].
Sugimoto Y; Nishii K; Miyata E; Fujieda A; Yamaguchi M; Masuya M; Katayama N
Rinsho Ketsueki; 2009 Apr; 50(4):289-94. PubMed ID: 19404022
[TBL] [Abstract][Full Text] [Related]
50. Quantitative identification of blood cell markers in human hematopoietic malignancies with diagnostic and prognostic significance.
Kusenda J
Neoplasma; 2008; 55(5):381-6. PubMed ID: 18665747
[TBL] [Abstract][Full Text] [Related]
51. Automated reticulocyte response is a good predictor of bone-marrow recovery in pediatric malignancies.
Das R; Rawal A; Garewal G; Marwaha RK; Vohra H
Pediatr Hematol Oncol; 2006 Jun; 23(4):299-305. PubMed ID: 16621771
[TBL] [Abstract][Full Text] [Related]
52. [Antibody therapy for hematopoietic malignancies and cell surface antigen testing].
Higashi K
Rinsho Byori; 2014 Apr; 62(4):352-8. PubMed ID: 25022064
[TBL] [Abstract][Full Text] [Related]
53. [The current status of leukemia genetic testing and the trial of its standardization].
Satoh Y; Yokota H; Kageyama Y; Ono Y; Yatomi Y
Rinsho Byori; 2008 May; 56(5):395-401. PubMed ID: 18546889
[TBL] [Abstract][Full Text] [Related]
54. Flow electroporation with pulsed electric fields for purging tumor cells.
Craiu A; Scadden D
Methods Mol Biol; 2008; 423():301-10. PubMed ID: 18370208
[TBL] [Abstract][Full Text] [Related]
55. [The examination of peripheral blood and bone marrow in the diagnosis of malignant blood diseases].
García Marcos MA; Ríos A
Sangre (Barc); 1996 Aug; 41(4):275-80. PubMed ID: 8984668
[No Abstract] [Full Text] [Related]
56. [Clinical value of interferon-alpha in the treatment of malignant hematologic diseases].
Harousseau JL
Presse Med; 1997 May; 26(18):857-9. PubMed ID: 9207887
[TBL] [Abstract][Full Text] [Related]
57. Serum-free media for cultures of primitive and mature hematopoietic cells.
Sandstrom CE; Miller WM; Papoutsakis ET
Biotechnol Bioeng; 1994 Apr; 43(8):706-33. PubMed ID: 18615795
[TBL] [Abstract][Full Text] [Related]
58. Set theory and the nosology of hematological malignancies: lymphomas are characterized by lymphoid differentiation, while leukemia definitions have no common property.
Portugal RD; Loureiro MM
Med Hypotheses; 2007; 69(1):52-6. PubMed ID: 17276609
[TBL] [Abstract][Full Text] [Related]
59. Flow Cytometry in Pediatric Hematopoietic Malignancies.
Li J; Wertheim G; Paessler M; Pillai V
Clin Lab Med; 2017 Dec; 37(4):879-893. PubMed ID: 29128074
[TBL] [Abstract][Full Text] [Related]
60. [Guidelines for performing surface antigen analysis on hematopoietic malignant cells (JCCLS H2-p V1.0)].
Japanese Committe for Clinical Laboratory Standards
Rinsho Byori; 2003 Sep; 51(9):910-26. PubMed ID: 14608985
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
